Targeted Medical (TRGM) 0.1000 $TRGM New Research from

New Post Public Reply Private Reply Replies (0) Message Board

May 18, 2015 at 6:57 PM

Targeted Medical (TRGM) 0.1000 $TRGM

New Research from Targeted Medical Pharma Finds a Link Between Obesity and Nutritional Deficiencies
Business Wire - Mon Apr 27, 2:00PM CDT
Obesity has reached epidemic proportions affecting nearly 78 million adults in the United States and has been linked with an increased risk of diabetes, heart disease, and cancer. Recent studies have suggested that obese patients have specific amino acid deficiencies that can contribute to obesity.

Targeted Medical Pharma Announces Changes in Management and Board of Directors
Business Wire - Thu Jan 29, 11:00AM CST
Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced several major changes that streamline operations and signify a commitment to revenue growth, cost containment and profitability. The Company has appointed Kim Giffoni, a co-founder and former Vice President of Foreign Sales at Targeted Medical Pharma, as the Chief Executive Officer. Dr. David Silver, former Chief Operating Officer and President at the Company, has been appointed Chief Medical Officer, and Marcus Charuvastra, the Director of Marketing, takes over as Vice President of Operations and Marketing.

Targeted Medical Pharma, Inc. - "Targeted Medical Pharma Third Quarter Recap"
ACCESSWIRE - Wed Dec 03, 2:01PM CST
NEW YORK, NY / ACCESSWIRE / December 3, 2014 / Targeted Medical Pharma, Inc. (OTCQB: TRGM) today published a new blog post on The Chairman's Blog, written by the Company's CEO and CSO, Dr. William Shell. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Targeted Medical Pharma Inc. "Treatment Update: Medical Foods for the Treatment of PTSD"
ACCESSWIRE - Mon Nov 03, 7:16AM CST
New York, NY / ACCESSWIRE / November 3, 2014 / Targeted Medical Pharma, Inc. (OTCQB: TRGM) today published a new blog post on The Chairman's Blog, written by the Company's CEO and CSO, Dr. William Shell. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Targeted Medical Pharma Releases Promising Trial Results for the Treatment of Posttraumatic Stress Disorder
Business Wire - Mon Oct 13, 5:00PM CDT
Targeted Medical Pharma, Inc. (OTCQB: TRGM), a drug discovery and development company, today announced the results of a clinical trial studying the amino acid based medical foods, Sentra AM and Sentra PM in Veterans suffering from symptoms associated with Posttraumatic Stress Disorder (PTSD).

Targeted Medical Pharma - "Developing New Therapies for Chronic Pain"
ACCESSWIRE - Tue Oct 07, 8:24AM CDT
New York, NY / October 7, 2014 / Targeted Medical Pharma, Inc. (OTCQB: TRGM) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Operating Officer, Dr. David Silver. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Targeted Medical Pharma's New Approach to Pain Management Targets Epidemic of Opioid and NSAID Over-Prescribing
Business Wire - Mon Oct 06, 5:00PM CDT
Targeted Medical Pharma, Inc. (OTCQB: TRGM) recently published the White Paper: Innovations in Pain Management discussing the epidemic of pain, the dangers of commonly prescribed pain medications and the benefits of Theramine as a clinically effective alternative to opioids and nonsteroidal anti-inflammatory (NSAID) drugs for the management of back pain and inflammation.

Targeted Medical Pharma to Present at Sachs Associated 14th Annual Biotech in Europe Forum for Global Partnering and Investment
Business Wire - Tue Sep 16, 9:00AM CDT
Targeted Medical Pharma (OTCQB:TRGM), today announced that William Shell, M.D., Chairman, CSO and CEO is scheduled to present the latest company information regarding the advances in therapeutic nutrition and medical foods technology, at the 14th Annual Biotech in Europe Forum at the Congress Center in Basel, Switzerland. The presentation is scheduled for September 30th, 2014 at 11:45 am in the Lima Room. Dr. Shell will also be a panelist in the discussion regarding advancements in Neuroscience at 3:30 pm.

Targeted Medical Pharma, Inc. - "Welcome to the Targeted Medical Pharma Blog"
ACCESSWIRE - Mon Sep 15, 8:31AM CDT
New York, NY / September 15, 2014 / Targeted Medical Pharma, Inc. (OTCQB: TRGM) today published a new blog post on The Chairman's Blog, written by the Company's CEO and CSO, Dr. William Shell. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Targeted Medical Pharma Reports Second Quarter 2014 Financial Results
Business Wire - Thu Aug 14, 4:30PM CDT
Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced financial results for its second quarter ended June 30, 2014. The Company posted increased revenues, gross profit and an increase in net income before interest, taxes, depreciation and amortization, and stock based compensation (Adjusted EBITDA*) on a quarter-over-quarter basis.

Targeted Medical Pharma Agrees to Sponsor a Clinical Trial Conducted by the United States Army and Henry M. Jackson Foundation for the Advancement of Military Medicine
Business Wire - Mon Jul 28, 10:21AM CDT
Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the completion of an agreement to sponsor an investigator-initiated study with the United States Army and The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. (HJF). The study, which is slated to start enrolling patients in Q2 of 2014, will involve the Company's medical food Theramine.

Tauriga Sciences enters into license agreement with Targeted Medical Pharma for launch of new cannabis complements product line
M2 - Thu Jul 17, 8:15AM CDT
Life sciences company Tauriga Sciences (Other OTC:TAUG) disclosed on Wednesday the launch of a non-exclusive licensing agreement under its "Cannabis Complements" product line.

Tauriga Sciences Inc. Signs License Agreement With Targeted Medical Pharma Inc.
GlobeNewswire - Wed Jul 16, 2:31PM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or the "Company"

, a diversified life sciences company, announced today it has signed a non-exclusive licensing agreement with Targeted Medical Pharma Inc. (OTCQB:TRGM) to reformulate and rebrand Targeted Medical's medical food formulations into dietary supplements as part of Tauriga's "Cannabis Complements" product line. Tauriga's new Cannabis Complements product line will be formally launched later in the summer and consists of dietary supplements and other natural wellness products that do not contain cannabis oil and that will attempt to address cannabis-related effects, such as anxiety, memory and cognitive functions, and appetite control. The products to be offered under the "Cannabis Complements" line will contain "GRAS" ingredients, the U.S. Food and Drug Administration's designation for ingredients that are "Generally Recognized as Safe".

Targeted Medical Pharma Appoints Two New Independent Members to the Board of Directors
Business Wire - Thu Jun 12, 5:00PM CDT
Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the addition of two independent members to the Company's board of directors. The Company welcomes back health care specialist Kerry Weems to the board as an independent director and chairman of the Nominating and Governance Committee, as well as corporate finance expert Paul Pelosi, Jr. as an independent director.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Intelligent Communication Forum Eyes Global Ecosystem Shift

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Quantum Space Joins $185M NASA Lunar Transport Deal

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Fibocom LTE Modules Test Drive Satellite Connectivity

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...